GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oragenics Inc (AMEX:OGEN) » Definitions » Cyclically Adjusted Price-to-FCF

Oragenics (Oragenics) Cyclically Adjusted Price-to-FCF : (As of Jun. 08, 2024)


View and export this data going back to 2003. Start your Free Trial

What is Oragenics Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Oragenics Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Oragenics's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oragenics Cyclically Adjusted Price-to-FCF Chart

Oragenics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Oragenics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Oragenics's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Oragenics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oragenics's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oragenics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Oragenics's Cyclically Adjusted Price-to-FCF falls into.



Oragenics Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Oragenics's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Oragenics's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.876/131.7762*131.7762
=-0.876

Current CPI (Mar. 2024) = 131.7762.

Oragenics Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 -28.267 100.560 -37.042
201409 -18.317 100.428 -24.035
201412 -21.200 99.070 -28.199
201503 -22.667 99.621 -29.983
201506 -15.836 100.684 -20.726
201509 -21.393 100.392 -28.081
201512 -26.381 99.792 -34.836
201603 -24.179 100.470 -31.713
201606 -28.657 101.688 -37.136
201609 -19.159 101.861 -24.786
201612 -23.951 101.863 -30.985
201703 -23.171 102.862 -29.684
201706 -21.524 103.349 -27.444
201709 -16.341 104.136 -20.678
201712 -16.573 104.011 -20.997
201803 -16.470 105.290 -20.613
201806 -22.810 106.317 -28.272
201809 -12.332 106.507 -15.258
201812 -6.065 105.998 -7.540
201903 -4.344 107.251 -5.337
201906 -4.536 108.070 -5.531
201909 -4.393 108.329 -5.344
201912 -5.120 108.420 -6.223
202003 -4.971 108.902 -6.015
202006 -5.555 108.767 -6.730
202009 -4.689 109.815 -5.627
202012 -3.206 109.897 -3.844
202103 -2.522 111.754 -2.974
202106 -1.076 114.631 -1.237
202109 -2.363 115.734 -2.691
202112 -1.137 117.630 -1.274
202203 -2.858 121.301 -3.105
202206 -1.744 125.017 -1.838
202209 -1.959 125.227 -2.061
202212 -1.102 125.222 -1.160
202303 -0.956 127.348 -0.989
202306 -1.273 128.729 -1.303
202309 -0.638 129.860 -0.647
202312 -0.426 129.419 -0.434
202403 -0.876 131.776 -0.876

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Oragenics  (AMEX:OGEN) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Oragenics Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Oragenics's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Oragenics (Oragenics) Business Description

Industry
Traded in Other Exchanges
Address
4902 Eisenhower Boulevard, Suite 125, Tampa, FL, USA, 33634
Oragenics Inc is engaged in research and the development of potential therapies to fight infectious diseases including coronaviruses and multidrug-resistant organisms. Its product (NT-CoV2-1) is an intranasal vaccine candidate to prevent coronavirus disease ("COVID-19") from the SARS-CoV-2 virus and variants thereof. Its focus on developing vaccines and novel antibiotics It is also developing a Terra CoV-2 immunization product candidate to combat the novel coronavirus.
Executives
Fred Telling director 501 ELLIOTT AVE. W., SUITE 400, SEATTLE WA 98119
John P Gandolfo director 62 TERRACE ROAD, WAYNE NJ 07470
Cassidy Bruce A. Sr. director C/O LOOP MEDIA, 700 N CENTRAL AVENUE, SUITE 430, GLENDALE CA 91203
Janet Huffman officer: CFO, Secretary and Treasurer 5317 FRUITVILLE RD SUITE 6, SARASOTA FL 34232
Robert C Koski director, 10 percent owner 1500 W UNIVERSITY PARKWAY, SARASOTA FL 34243
Michael O'keefe Sullivan officer: CFO, Secretary and Treasurer 3000 BAYPORT DRIVE, SUITE 685, TAMPA FL 33607
Joseph Hernandez 10 percent owner C/O MICROLIN BIO, INC., NEW YORK NY 10022
Kimberly M Murphy director 101 EAST KENNEDY BLVD., SUITE 2800, TAMPA FL 33602
Koski Family Lp 10 percent owner 1500 W UNIVERSITY PARKWAY, SARASOTA FL 34243
Randal J Kirk 10 percent owner 1881 GROVE AVENUE, RADFORD VA 24141
Alan Joslyn director, officer: CEO and President 39 OLD RIDGEBURY ROAD, DANBURY CT 06810
Charles L Pope director 4902 EISENHOWER BOULEVARD, TAMPA FL 33634
Christine L Koski director, 10 percent owner 1500 WEST UNIVERSITY PARKWAY, SARASOTA FL 34243
Beverly Koski 10 percent owner
Thomas L Koski 10 percent owner

Oragenics (Oragenics) Headlines

From GuruFocus